Published

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: JAMA psychiatry
Date: 2024-06-01
Source: PubMed
DOI: 10.1001/jamapsychiatry.2023.4685
PubMed: 38055270

Authors

Aaronson ST van der Vaart A Miller T LaPratt J Swartz K Shoultz A Lauterbach M Sackeim HA Suppes T

Watch author

Derived topics and classifications

psilocybin Depression Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 7 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview2026-07-13 Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study2026-07-01 Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”2026-06-30 Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations2026-06-01 Insights into psilocybin use among people with bipolar disorder: A thematic analysis of Reddit posts2026-05-01 Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications2026-04-01 Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.2024-06-01

Related papers

Efficacy and Safety of Psilocybin in Treatment-Resistant Major DepressionJAMA Psychiatry · 2026-05-01 A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.Psychotherapy (Chicago, Ill.) · 2025-09-01 Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted PsychotherapyClinicalTrials.gov · 2026-04-22 Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory DepressionClinicalTrials.gov · 2026-03-27 A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With FibromyalgiaClinicalTrials.gov · 2025-04-16 Psilocybin-assisted Interpersonal Therapy for DepressionClinicalTrials.gov · 2025-04-09 Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialPsychotherapy and Psychosomatics · 2026-05-27 The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-08